ACX-362E [Ibezapolstat] for Oral Treatment of Recurrent Clostridioides Difficile Infection (NCT07513285)
A Phase 2 Interventional, Open-Label, Single-Arm Trial of Oral Ibezapolstat (ACX-362E) for Treatment and Reduction of Recurrent Clostridioides Difficile Infection in Patients With Multiple Recurrent Infections (IBZ-PATHFINDER)
🩺 Plain-English Summary (8th-Grade Level)
Single-arm trial to evaluate the safety and efficacy of ACX-362E \[ibezapolstat\] in patients with recurrent C. difficile infection (CDI).
Who can join: Review the eligibility criteria below.
Location: UC Davis Medical Center — Sacramento, California
Age range: 18 Years to 90 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (15 Sites)
- UC Davis Medical Center — Sacramento, California
- Gastroenterolgy Center of Conneticut — Hamden, Connecticut
- Florida International Medical Research — Coral Gables, Florida
- L&A Morales Healthcare, Inc — Hialeah, Florida
- San Marcus Research Clinc, Inc — Miami Lakes, Florida
- Belis Delgado, MD PA — Miami Springs, Florida
- Infectious Disease Consultants of Georgia — Athens, Georgia
- Snake River Research PLLC — Idaho Falls, Idaho
- Endevour Health — Skokie, Illinois
- Newton-Wellesley Hospital — Newton, Massachusetts
- University of Massachusetts Memorial Healthcare — Worcester, Massachusetts
- Henry Ford Hospital — Detroit, Michigan
- DiGiovanna Institute for Medical Education and Research — Massapequa, New York
- Romano, Pontzer & Associated — Pittsburgh, Pennsylvania
- University of Utah — Salt Lake City, Utah
📞 Contact the Study Coordinator
Phone: (774) 266-5290
Email: dee.rodriguez@acurxpharma.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Clostridium Difficile Infection Recurrence
Explore by condition: All Clostridium Difficile Infection Recurrence clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.